| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/17/2004 | WO2004007742A3 Chromosome 6 and 9 genes involved in premature canities |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2003051911A3 Gmg-5 polynucleotides and polypeptides and uses thereof |
| 06/17/2004 | WO2003026566A3 Atlastin |
| 06/17/2004 | WO2003022228A3 Method for producing transgenic birds and fish |
| 06/17/2004 | WO2003015689A3 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 06/17/2004 | US20040117875 Systems and methods for delivering interferon to a subject |
| 06/17/2004 | US20040116689 can comprise DNA, RNA, PNA, or any combination or chimera thereof |
| 06/17/2004 | US20040116684 Progenitor viral nucleotide sequences for generating vaccines to prevent viral infection during xenogenic tissue and/or organ transplantation; tissue engineering |
| 06/17/2004 | US20040116652 Method for producing and using novel human defensins as biologically active proteins for treating infections and other diseases |
| 06/17/2004 | US20040116496 Asymmetric Disulfides and methods of using same |
| 06/17/2004 | US20040116372 to decrease the number of cells which may accumulate in chronic inflammatory disease by enhancing apoptosis at the site of increased cell number via gene therapy |
| 06/17/2004 | US20040116371 Methods for polysaccharide adhesion synthesis modulation |
| 06/17/2004 | US20040116370 a nucleic acid encoding an immunogenic polypeptide; a lipid; and a transition metal enhancer ZnCl2 |
| 06/17/2004 | US20040116369 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 06/17/2004 | US20040116366 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
| 06/17/2004 | US20040116338 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 06/17/2004 | US20040115800 Expression vector comprising sequences which code for drug resistant cytidine deaminase and identify transduced and/or transfected cells; gene therapy; anticarcinogenic agnets; viricides |
| 06/17/2004 | US20040115789 Packaging cell lines for the continuous production of alphavirus vectors |
| 06/17/2004 | US20040115788 Hybrid adeno-retroviral vector for the transfection of cells |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115690 Method of detecting inflammatory lung disorders |
| 06/17/2004 | US20040115681 Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells |
| 06/17/2004 | US20040115667 Dna-sequences, which code for an apoptosis signal transduction protein |
| 06/17/2004 | US20040115656 Androgen receptor down-regulatory-associated proteins(ARDAPs) for use in reduction of transactivation activity of androgen receptors and treatment of tumors; gene expression inhibition and anticarcinogenic agents |
| 06/17/2004 | US20040115652 Antisense oligonucleotides for controlling expression of receptor tyrosine kinase gene and treatment of hyperproliferative disorders; gene expression inhibition |
| 06/17/2004 | US20040115636 Modulation of interleukin 18 expression |
| 06/17/2004 | US20040115635 Modulation of PTPN13 expression |
| 06/17/2004 | US20040115633 Modulation of mitochondrial ribosome protein S16 expression |
| 06/17/2004 | US20040115622 Mixture of peptides originating from a Nef protein and applications thereof |
| 06/17/2004 | US20040115620 Adenoviral replicons |
| 06/17/2004 | US20040115254 Microcapsules and methods of use |
| 06/17/2004 | US20040115199 Method for down-regulating osteoprotegerin ligand activity |
| 06/17/2004 | US20040115195 treating bone disorders resulting in increased trabecular bone formation, decreased osteoblast and osteocyte apoptosis and increased osteoprogenitor differentiation |
| 06/17/2004 | US20040115186 a urease enzyme, and having associated with it a chemical entity effective to enhance the delivery of the enzyme to cancer cells |
| 06/17/2004 | US20040115129 Nucleic acid sequence 1 or 3; amino acid sequence 2 or 4 |
| 06/17/2004 | CA2508514A1 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 06/17/2004 | CA2507990A1 Novel ifngamma-like polypeptides |
| 06/17/2004 | CA2507534A1 Methods for treating or preventing angiogenesis-dependent symptoms |
| 06/17/2004 | CA2507036A1 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | CA2485341A1 Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses |
| 06/16/2004 | EP1428887A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 06/16/2004 | EP1428886A1 Improved retroviral vectors for gene therapy |
| 06/16/2004 | EP1428879A1 Polynucleotide vaccine |
| 06/16/2004 | EP1428875A1 Method of diagnosis of obesity |
| 06/16/2004 | EP1428834A1 Ligands for flt3 receptors |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427837A2 Modular transfection systems |
| 06/16/2004 | EP1427836A2 Pseudotyped retroviral vector system |
| 06/16/2004 | EP1427828A2 Random integration of a polynucleotide after in vivo linearization |
| 06/16/2004 | EP1427827A2 Synthetic hcv envelope proteins and their use for vaccination |
| 06/16/2004 | EP1427826A2 Hiv-gag codon-optimised dna vaccines |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427815A2 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
| 06/16/2004 | EP1427806A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 06/16/2004 | EP1427758A2 Compositions and methods of treating diabetes |
| 06/16/2004 | EP1427754A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 06/16/2004 | EP1427450A2 Inhibition of rna function by delivery of inhibitors to animal cells |
| 06/16/2004 | EP1427449A1 Anti-cancer agents comprising disintegrin genes and the treating methods |
| 06/16/2004 | EP1427443A1 Vaccine using papilloma virus e proteins delivered by viral vector |
| 06/16/2004 | EP1427441A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427426A2 Gpi-anchored cytokines |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1214074B1 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/16/2004 | EP1071806B1 Recombinant adeno-associated viral vector encoding alpha-1-antitrypsin for gene therapy |
| 06/16/2004 | EP1064404B1 P53-regulated genes |
| 06/16/2004 | EP0789563B1 Hepatitis virus b and c vaccines |
| 06/16/2004 | CN1505526A Compositions and methods for wt1 specific immunotherapy |
| 06/16/2004 | CN1505522A Stimulation of thymus for vaccination development |
| 06/16/2004 | CN1504571A Trichosanthin suicide ENH-TCS, recombination carrier and application thereof |
| 06/16/2004 | CN1504476A Polynucleotide for identifying polypeptide OT3 and coding OT3 of tumor cell and uses thereof |
| 06/16/2004 | CN1504235A Tie2 receptor-induced gene transfer system for treating target tumor genes |
| 06/16/2004 | CN1153567C Scale production method of forming microparticles |
| 06/15/2004 | US6750333 Used as a drug particularly in gene therapy |
| 06/15/2004 | US6750327 Compositions and method for determining the presence of human PTTG peptide in a sample |
| 06/15/2004 | US6750206 Recombinant nucleic acid vector comprising a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface |
| 06/15/2004 | US6750198 Treating disorders characterized by a reduction in pigmentation comprising administering an effective amount of the protein dcoh |
| 06/15/2004 | US6750194 Administering to the subject a safe and effective amount of a vpac receptor agonist selected from the group consisting of ro 25-1553, and pacap-38 |
| 06/15/2004 | US6750058 For treatment and prevention of human and animal diseases; in particular capable of dispensing to suitable target cells nucleic sequences, proteins, peptides and chemical substances via transfection |
| 06/15/2004 | US6750043 Expression vector for use in the expression of heterologous protein in cells |
| 06/15/2004 | US6750034 Useful as therapeutic agents for cancer, skin disorders, neuropathic pain, inflammatory, or coagulation diathesis/thrombosis; may also be useful for laundry detergents and skin care products; derived from humans |
| 06/15/2004 | US6750019 Antisense modulation of insulin-like growth factor binding protein 5 expression |
| 06/15/2004 | US6750012 For identifying compounds that do not induce motor side effects |
| 06/15/2004 | US6749863 Targeted liposome gene delivery |
| 06/15/2004 | US6749854 Use of OX-2 to inhibit fetal loss |
| 06/15/2004 | US6749850 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 06/15/2004 | US6749845 Modulated release particles for lung delivery |
| 06/15/2004 | CA2285921C Composition and method for treatment of cmv infections |
| 06/10/2004 | WO2004048591A2 Methods for cohort selection and longevity studies |
| 06/10/2004 | WO2004048583A2 Compositions and systems for the regulation of genes |
| 06/10/2004 | WO2004048582A2 Recombinant poxvirus comprising at least two cowpox ati promoters |
| 06/10/2004 | WO2004048574A1 Immunoreceptor proteins |
| 06/10/2004 | WO2004048570A1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR |
| 06/10/2004 | WO2004048568A1 UTILIZATION OF mKank GENE IN CANTER THERAPY, CANER DETECTION AND DRUG DISCOVERY |
| 06/10/2004 | WO2004048548A2 Methods for identifying risk of breast cancer and treatments thereof |
| 06/10/2004 | WO2004048533A2 Modulation of forkhead box c2 expression |
| 06/10/2004 | WO2004048524A2 Modulation of stat2 expression |
| 06/10/2004 | WO2004048522A2 Modulation of huntingtin interacting protein 2 expression |
| 06/10/2004 | WO2004048519A2 Treatment of mammalian reaction to ige interactions |